Purpose: To analyse ophthalmological adverse events associated with mitogenactivated protein kinase kinase (MEK) inhibition with pimasertib treatment for metastatic cutaneous melanoma (CM). Methods: In this prospective observational, cohort-based, cross-sectional study, eight patients treated with the MEK inhibitor pimasertib received a complete ophthalmic examination. This included Early Treatment of Diabetic Retinopathy Study best-corrected visual acuity, visual field testing, colour vision testing, slit-lamp examination, applanation tonometry, indirect ophthalmoscopy, digital colour fundus photography and optical coherence tomography (OCT). In selected cases, fluorescein angiography was performed. Results: Serous subretinal fluid (SRF) developed in all patients, within a time frame of 9-27 days after the start of treatment. The fovea was involved in six of eight patients (75%). None of the patients with foveal SRF [excluding a patient who developed a bilateral retinal vein occlusion (RVO)] experienced visual symptoms. Subretinal fluid (SRF) decreased or resolved in all patients, despite continuation of study medication in six of eight patients (75%). Complaints in the CM patient (13%) consisted of experiencing a dark fleck in the inferior part of the visual field of the right eye 1 week after the start of treatment, due to an RVO. Subsequent intravitreal bevacizumab treatment resulted in functional and anatomical improvement. Conclusion: Patients with metastatic CM who are treated with the MEK inhibitor pimasertib are at high risk of development of ocular adverse events including serous retinopathy and possibly RVO, stressing the need of adequate ophthalmological follow-upincludingOCTduringadministrationofpimasertib,despitethefactthatSRF generallydoesnotleadtoophthalmologicalcomplaints.
Introduction
Spectral-domain optical coherence tomography (SD-OCT) is a sensitive means to detect serous retinopathy, which is defined as retinal lesions on ophthalmoscopy corresponding to a localized separation of the neuroretina and retinal pigment epithelium (RPE) (van Dijk et al. 2015) . It may occur as an independent entity but may also be associated with a broad spectrum of other diseases or may follow the use of certain drugs (Ghazi & Green 2002) . We and others recently described that serous retinopathy is seen in patients with metastatic melanoma during the treatment with mitogen-activated protein kinase kinase (MEK) inhibitors such as binimetinib (van Dijk et al. 2015; Weber et al. 2016) , cobimetinib (McCannel et al. 2014) , trametinib ) and RO5126766 (Martinez-Garcia et al. 2012) . Luckily, in many cases, vision is not affected by the treatment, but serious problems including retinal vein occlusion (RVO) may occur (LoRusso et al. 2010; Leijen et al. 2012) .
As treatment options for metastatic malignant cutaneous melanoma (CM) are scarce, much effort is being put into the development of possible new treatments for this patient group. One of the target pathways for treatment is the MAPK signalling (Ras-Raf-MEK-extracellular signal-regulated kinase) pathway. A broad spectrum of cellular processes is coordinated by this pathway. Activation of the MAPK pathway influences processes such as cell differentiation and metabolism, cell migration and cell death (Krishna & Narang 2008) . Although visual symptoms may be absent or relatively mild in patients to whom MEK inhibition is prescribed, OCT imaging has shown that some of the MEK inhibitors induce retinal changes in a high percentage of patients (Flaherty et al. 2012; Ascierto et al. 2013; McCannel et al. 2014; UrnerBloch et al. 2014; van Dijk et al. 2015) .
Preclinical studies have shown that the new MEK inhibitor pimasertib displays activity against RAS-and BRAF-mutated cell lines (Kim et al. 2010; Yoon et al. 2011) . Moreover, induction of apoptosis in BRAF-mutated human malignant melanoma cell lines has been described after the administration of a combination of pimasertib and the BRAF inhibitor PLX4032, whereas either drug alone did not (Park et al. 2013 ). In the first human trial IMP28062, activity against NRASmutated tumours could be detected after prescription of pimasertib. In a recently published report of a patient with metastatic ovarian cancer, bilateral multifocal retinal detachments were described 2 days after the start of pimasertib (AlAli et al. 2016) . This patient developed complaints of blurred vision, and treatment was discontinued. Three days after stopping pimasertib treatment, ocular complaints and lesions had disappeared (AlAli et al. 2016) . The occurrence of serous retinal detachments in patients, to whom pimasertib was prescribed, was not further specified in other studies (Houede et al. 2011; Macarulla et al. 2015) . In one of these studies, the occurrence of an RVO in a patient was also not discussed in detail (Houede et al. 2011) . No other ocular adverse events during the prescription of pimasertib have been reported so far.
We hypothesized that this drug may also lead to subretinal fluid (SRF) and wondered whether SRF would occur in only in a sensitive subset of patients, or that it might be a general phenomenon. As patients are in quite a good general condition when using this treatment, we were able to perform a prospective study of patients using the new MEK inhibitor pimasertib and included highresolution OCT imaging to examine the macular area in detail.
Materials and Methods

Patient characteristics
Eight patients from an academic medical centre (Erasmus University Medical Centre, Rotterdam, the Netherlands) were included in this study. All patients were diagnosed with a measurable, histologically or cytologically confirmed, locally advanced or metastatic NRASmutated malignant CM. Patients with a medical history of retinal degenerative disease, uveitis or RVO were excluded. Local ethics committee approved the study. Each patient gave written informed consent, and the study was performed in accordance with the Declaration of Helsinki. The clinical trial was registered in the Clinical Trial Register with number NCT01693068. Patients were included in this trial from September 2013 to June 2014.
Treatment
All patients received pimasertib in a randomized phase II trial, in which the comparator arm was chemotherapy with dacarbazine (intravenous administration at dose of 1000 mg per square metre of body surface area, every 3 weeks). Patients received 60 mg of pimasertib orally twice a day, continuously for 21 days (defined as one treatment cycle, for scheduling purposes). Within this trial, seven patients were primarily randomized to pimasertib, whereas one patient made a crossover to treatment with pimasertib after having developed progressive disease upon chemotherapy with dacarbazine.
Ophthalmic examinations
All patients received complete ophthalmic examination, including Early Treatment of Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) testing, visual field testing, colour vision testing using the Desaturated Panel D-15 test, slit-lamp examination, intraocular pressure measurement, indirect ophthalmoscopy, digital colour fundus photography (Topcon Corporation, Tokyo, Japan) and OCT using the SD-OCT [Spectralis HRA + OCT (Heidelberg Engineering, Heidelberg, Germany)], before start of the study. Part of these examinations was performed after dilation of pupils by topical administration of 1% tropicamide and 5% phenylephrine drops. Moreover, study protocol instructed the BCVA measurement at every evaluation visit: at the beginning of treatment cycle 2 and at the beginning of every subsequent odd treatment cycle. At these evaluation visits, slit-lamp examination and assessment of the posterior pole using indirect ophthalmoscopy were also prescribed to be executed, together with OCT scanning. When ETDRS BCVA testing was not available, Snellen BCVA was determined, and a previously established conversion method was used to achieve ETDRS values (Gregori et al. 2010) .
In patients with visual disturbances or abnormal retinal findings on ophthalmological assessments, fluorescein angiography was performed with the spectral-domain OCT. Treatment had to be interrupted when a serous retinal detachment with a decrease in ETDRS BCVA of ≥15 letters occurred. A serous retinal detachment was defined as a localized separation of the neuroretina and RPE on OCT, with an accumulation of SRF between these layers. Restart of treatment could only be scheduled after full resolution of the detachment and full recovery of vision within 2 weeks, after weekly follow-up visits. In case of the occurrence of an RVO, the study medication had to be stopped, unless the event resolved within 2 weeks.
Safety and efficacy monitoring
After clinical assessment at the evaluation visits at the Department of Oncology, the dose of study medication was reduced, or medication was discontinued, when either unacceptable signs of toxicity or disease progression had developed. Subjects with documented tumour progression on the dacarbazine arm could choose to switch to receiving pimasertib.
Statistical analysis
Both ETDRS BCVA at the time-point of most pronounced SRF on OCT and at final follow-up were compared to ETDRS BCVA at initial screening, using an independent t-test in IBM SPSS Statistics, version 23.0 (IBM Corp., Armonk, NY, USA).
Results
The eight CM patients (four male, four female) had a mean age of 62.9 years (median: 64 years; range, 56-67 years). The clinical patient characteristics are summarized in Table 1 .
During this study, one patient (13%) developed visual complaints, consisting of experiencing a dark fleck in the inferior part of the visual field of the right eye. These complaints started 1 week after the restart of pimasertib treatment, after a previous discontinuation because of a reversible decrease in left ventricular ejection fraction. In the right eye, ETDRS BCVA had dropped from 95 to 67 letters, while ETDRS BCVA of the left eye had not changed at the time of visual complaints. Indirect ophthalmoscopy and fluorescein angiography led to the diagnosis of a hemi-RVO of the superior temporal vein of the right eye and an asymptomatic mild hemi-RVO of the inferior temporal retinal vein of the left eye ( Fig. 1A-L) . Because of cystoid macular oedema, a single intravitreal injection of bevacizumab in the right eye was given to this patient, after which ETDRS BCVA recovered to 89 letters at follow-up visit 8 days later ( Fig. 1M-P) . Because of the need for palliative care, which this patient preferred to receive in another hospital, and because of the good functional and anatomical result of this single injection, no additional follow-up was scheduled.
Optical coherence tomography (OCT) indicated that SRF developed in 16 of 16 (100%) eyes. None of the patients (excluding the patient with RVO) experienced visual symptoms. Moreover, no measurable significant influence on visual acuity could be detected, as (converted) median BCVA ETDRS was 88 letters (range, 77-93 letters) at screening, 87 letters (range, 66-98 letters) at the moment of most prominent SRF on OCT and 89 letters (range, 75-98 letters) at the final follow-up visit. Differences in ETDRS BCVA were not statistically significant [p = 0.58 (screening versus most prominent SRF), p = 0.31 (most prominent SRF versus final follow-up visit) and p = 0.51 (screening versus final follow-up visit)].
Ophthalmoscopy revealed transparent to yellowish vitelliform lesions at the time that SRF was observed on OCT (Figs 1D,K,L and 2A), whereas either no abnormalities or mild RPE changes were observed after disappearance of SRF. The SRF was bilateral and fairly symmetrical ( Fig. 2K-T) . These lesions were seen in all patients at the time of their first OCT after the start of the study medication, which was performed after 9-27 days (median: 20 days). Foveal SRF accumulation was present in six of eight patients (75%). The centre of these lesions was hyperreflective on infrared reflectance (IRR) imaging, and the lesions were surrounded by a hyporeflective zone. On OCT, SRF was detected extrafoveally in all eight patients (Figs 1K,L and 2D,I,J). The median total number of extrafoveal lesions in the posterior pole, based on a 30°IRR photograph, was 6 (mean: 5, range, 3-13 lesions) in the 16 eyes.
At last ophthalmological follow-up at 14-126 days (median: 81 days) after the first appearance of SRF, the SRF had disappeared in both eyes in five of eight patients (63%). In the patient who received intravitreal bevacizumab, resolution of both cystoid macular oedema and SRF had occurred. Administration of pimasertib had been discontinued in this patient. In the other four patients, SRF disappeared spontaneously while pimasertib was either still administered according to the original dose (two patients) or dose of pimasertib was reduced (one patient), or pimasertib was discontinued because of a decrease in left ventricular ejection fraction (one patient). Three patients had persistent SRF, during treatment with 60, 60 and 30 mg of pimasertib twice a day, respectively. However, during follow-up, the amount of SRF had decreased in all three patients. Colour vision testing and visual field testing revealed no significant changes, despite the fact that macular SRF accumulation had occurred during pimasertib treatment. For all patients, information on the occurrence and evolution of SRF, and the possible relationship with orally administered dose of pimasertib has been depicted in Fig. 3 .
During the period of the administration of study medication in one patient who had previously been diagnosed with bilateral diabetic macular oedema (DME), (Fig. 4A-D) oedema had increased unilaterally at ophthalmological follow-up, 9 days after the start of study medication (Fig. 4E-F) . This patient also developed bilateral foveal SRF. No signs of other ophthalmological diseases were detected during follow-up. Eleven days later, SRF and oedema had decreased spontaneously (Fig. 4G,H) . At final follow-up 106 days later, only minimal unilateral foveal SRF remained (Fig. 4I,J) . Ophthalmic characteristics of all patients are summarized in Table 1 .
Discussion
Spectral-domain OCT (SD-OCT) is a sensitive means to detect a typical serous retinopathy in patients treated with MEK inhibitors such as pimasertib. Despite these striking MEK inhibitorassociated retinal abnormalities in all eight metastatic CM patients, all but one patient remained asymptomatic. This patient experienced central vision loss due to bilateral RVO, which responded to intravitreal bevacizumab treatment. Lesions occurred both foveally and extrafoveally in most of the eight patients, indicating a more extensive dysfunction of the retina and/or RPE that extended beyond the fovea. Serous retinopathy had either disappeared or decreased at the last ophthalmological follow-up in all patients.
The exact pathogenesis of both serous retinopathy and RVO associated with MEK inhibitor treatment is as yet unclear. A time-dependent and reversible serous retinopathy, resembling the clinical picture we present in the current study, was previously described in association with several other MEK inhibitors such as cobimetinib (McCannel et al. 2014) , trametinib , and RO5126766 (Martinez-Garcia et al. 2012). We described this specific phenotype by a mildly symptomatic, time-dependent and reversible accumulation of both foveal and extrafoveal serous SRF, with abnormalities on electro-oculography but without any evidence of choroidal abnormalities (van Dijk et al. 2015) . This serous retinopathy is most probably related to a class effect of this type of drugs, and thereby an on-target side-effect of treatment (Duncan et al. 2015; Kurbel et al. 2015) , although pharmacological differences between several MEK inhibitors exist (Hatzivassiliou et al. 2010 ). We have previously described prolonged abnormalities on electro-oculography in patients with transient binimetinibassociated serous retinopathy, indicating panretinal RPE dysfunction and dysfunction of the RPE pump (McCannel et al. 2014; van Dijk et al. 2015) . In addition, anti-RPE and antiretinal autoantibodies may play a role (van Dijk et al. 2015) . In a cell model of RPE and neuroretina, binimetinib administration resulted in inactivation of the MAPK pathway, and discontinuation of administration of the MEK inhibitor binimetinib led to reactivation, mimicking the mild and reversible retinopathy (van Dijk et al. 2016) . The occurrence of an RVO, during the prescription of MEK inhibition, has also been described previously in up to 5% of patients (LoRusso et al. 2010; Houede et al. 2011; Leijen et al. 2012) . Mitogenactivated protein kinase kinase (MEK) inhibitors could influence the vasculature of the retina, leading to both this serous retinopathy and RVO (van der Noll et al. 2013; van Dijk et al. 2015) . The RVO that occurred in one of our patients could have been associated with the previous reversible decrease in left ventricular ejection fraction in this case, which had been detected 3 weeks before the diagnosis of RVO had been established. Moreover, after oral administration of the MEK inhibitor PD0325901 to rats, retinal gene expression suggested an increase in inflammatory and oxidative stress response, endothelial and blood-retinal barrier damage, and effects on blood coagulation, possibly characteristic for RVO (Huang et al. 2009 ). Effects of oxidative stress and endothelial cell inflammation could lead to vascular hyperpermeability and damage to the blood-retinal barrier (Huang et al. 2009 ). Moreover, an imbalance between thrombosis and fibrinolysis has previously been described to play an active role in the development of RVO (Lip et al. 1998; Rehak & Rehak 2008) . Mitogen-activated protein kinase kinase (MEK)-associated serous retinopathy has to be discerned from several other retinal diseases. In contrast to central serous chorioretinopathy, in which lesions usually start unilaterally or bilateral asymmetrically, the MEKassociated serous retinopathy is not associated with RPE detachments on OCT, and there are no "hot spots" of trans-RPE subretinal leakage on fluorescein angiography (McCannel et al. 2014; Urner-Bloch et al. 2014) . In cancer-associated retinopathy, melanoma-associated retinopathy or nonneoplastic autoimmune retinopathy, symptoms may include a relatively rapid-onset photopsia, night blindness, scotomas and progressive visual field loss (Heckenlively & Ferreyra 2008) . Interestingly, this spectrum of autoimmune retinopathy is associated with antiretinal and/or anti-RPE antibodies, which we have also described in association with MEK inhibitor-associated serous retinopathy (van Dijk et al. 2015) . Hereditary retinal dystrophies such as autosomal dominant inherited Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy usually have an earlier onset in combination with typical fundus lesions and a markedly abnormal electro-oculogram (Boon et al. 2009 ).
In conclusion, we show that serous retinopathy associated with MEK inhibition treatment such as pimasertib is very common. This serous retinopathy generally does not lead to marked ophthalmological complaints (van Dijk et al. 2015) , and lesions may resolve despite continuous treatment. Therefore, discontinuation of treatment in most patients with metastatic cancer is not necessary. As ophthalmological complaints may occur in a noteworthy number of patients (van Dijk et al. 2015) , and as survival may increase in these patients because of the use of this new type of treatment for metastatic melanoma, performing OCT scanning before, during and after MEK inhibition treatment may be advisable for monitoring and followup of fundus lesions. Another ophthalmological side-effect of MEK inhibition is RVO, which can cause visual complaints that require therapeutic intervention. Especially, OCT follow-up is able to precisely monitor such abnormalities even in patients that remain asymptomatic. It is currently unclear if MEK inhibitor-associated serous retinopathy correlates with other clinical parameters of MEK inhibition treatment such as treatment response of metastases (van Dijk et al. 2015) . Further studies are needed to unravel the exact pathogenesis and clinical consequences of MEK inhibitor-associated ophthalmological adverse events.
